Для доступа к научной работе требуется оплата - 200 000 UZS.
Чтобы произвести оплату войдите под своим логином.
Диагностика антифосфолипидного синдрома при цереброваскулярных нарушениях
inLibrary
Google Scholar
Журнал:
Выпуск:
Поделиться
Для доступа к научной работе требуется оплата - 200 000 UZS.
Чтобы произвести оплату войдите под своим логином.
Маджидова, Я., & Бустанов, О. (2024). Диагностика антифосфолипидного синдрома при цереброваскулярных нарушениях. Каталог монографий, 1(1), 3–72. извлечено от https://inlibrary.uz/index.php/monographs/article/view/19771
Ключевые слова:
Аннотация
В настоящее время зависимость от многих видов клинических проявлений АФС стала междисциплинарной проблемой, широко изучаемой различными врачебными специальностями во всем мире: неврологом, ревматологом, акушер-гинекологом, дерматологом и др. L.A. для изучения АФС в России. Калашников (невролог), Е.А. Насонов (ревматолог), Т.М. Решетник (ревматолог), З.С. Баркаган (гематолог) и другие внесли значительный вклад. Первая публикация по изучению АФС была опубликована в 1990 г. в Украине врачом-гинекологом профессором Т.Н. Деминой и неврологом профессором С.К. Принадлежащие Евтушенко и его ученикам [1; 143-146-с., 3, 4; 39-41-б 84-86-б.]. Результаты многолетних исследований неврологических аспектов (аспектов) АФС на базе Донецкого национального медицинского университета представили профессор С.К. Роль антифосфолипидных антител в развитии цереброваскулярной патологии у лиц молодого возраста под руководством Евтушенко (М.Ф. Иванова), «Детский церебральный паралич у детей, рожденных от матерей с серопозитивным и серонегативным вариантами антифосфолипидного синдрома» (М.А. Москаленко в 2003 г.). завершенный. В 2004 году профессор С.К. Евтушенко посетил клинику профессора Г. Хьюза в Лондоне и познакомился с фондом Lupus Journal Foundation, который публикует лабораторные работы, системные заболевания соединительной ткани и научные работы, связанные с АФС. В последние годы увеличилось количество публикаций украинских авторов. По данным зарубежных и отечественных авторов, частота гиперкоагуляции АФС в общей популяции среди лиц молодого возраста составляет 5% [19; 513-518-б., 20; Стр. 12-17, 39; Стр. 9-20]. Заболевание наблюдается у детей даже у новорожденных [17, 26; Стр. 21-25, 39; Стр. 9-20]. В общей популяции АФС чаще выявляют у женщин, чем у мужчин (соотношение 1:5), вероятно, в связи с предрасположенностью женщин к системным заболеваниям соединительной ткани [6; 9-б.]. В 11,8% случаев инсульт был ассоциирован с АФС у молодых женщин [20; Стр. 12-17].
Библиографические ссылки
Abreu M. M., Danowski A., Wahl D. G., Amigo M. C., Tektonidou M. & Pacheco M. S. Therelevanceof “non-criteria” clinical manifestation sofantip hospholipid syndrome: 14th International Congresson Antiphospholipid Antibodies Technical Task Force Reporton Antiphospholipid Syndrome Clinical Features. // AutoimmRev. - 2015. - 14. - 401-414.
Asherson R. A. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines // Lupus. - 2003. - Vol. 12. - P. 530-534.
Berkun Y, Simchen M., Strauss T. et al. Antiphospholipid antibodies in neonates with stroke — a unique entity or variant of antiphospholipid syndrome? // Lupus. — 2014. — Vol. 23, N 10. — P. 986-993.
Bettacchioli E., Nafai S., Renaudineau Y. Newsand meta- analysisregardinganti-Beta 2 glycoprotein I antibodiesandtheir determination. // ClinImmunol. - 2019. - 205. - 106-115. Л*
Brandt J.T. Criteria for the diagnosis of lupus anticoagulants: an update: on behalf of the Subcommittee on Lupus Anticoagulant /Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH // Thromb. Haemost. - 1995. - Vol. 74. -P. 1185-1190.
Brey R. Differential diagnosis of central nervous system manifestations of the antiphospholipid syndrome. J Autoimmun 2000; 15:133-138.
BruschA. The Significanceof Anti-Beta-2-Glycoprotein I Antibodies in Antiphospholipid Syndrome. // Antibodies.- 2016. - 5. - 16-26.
Bucciarelli S., Espinosa G., Cervera R. et al. Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients // Arthritis Rheumotol. - 2006. - V. 54. - P. 2568-2576.
Cavazzana I., Manuela N., Irene C. et al. Complement activation in anti-phospholipid syndrome: a clue for an inflammatory process? // J. Autoimm. - 2007. - V. 28. - P. 160-164.
Cervera R, Espinosa G. Update on the catastrophic antiphospholipid syndrome and the "CAPS Registry". Seminars in Thrombosis and Hemostasis. Vol.38, N4/2012; 333-337.
Cervera R., Khamashta M., Shoenfeld Y. et al. Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients // Ann. Rheum. Dis. - 2009. - V. 68. - P. 1428¬1432.
Cervera R., Piette J., Font J. et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients // Arthritis Rheum. - 2002. - V. 46. - P. 1019-1027.
Cervera, R. Antiphospholipid syndrome / R. Cervera // Thromb. Res. — 2017. — Vol. 151, Suppl. 1. — P. 43-47.
Clark C. A., Spitzer K. A, Laskin C. A. et al. Heparin treatment in antiphospholipid syndrome with recurrent pregnancy loss // Obstet. Gynecol. - 2010. Vol.116 (4). - P.997-998
Cohen D., Berger S. P., Steup-Beekman G. M. et al. Diagnosis and management of the antiphospholipid syndrome // BMJ. 2010. - Vol.340. -P.2541.
Cohen D., Buurma A., Goemaere N. N. et al. Classical complement activation as a footprint for murine and human antiphospholipid antibody-induced fetal loss // J. Pathol. - 2011. -V. 225. -P. 502-511.
Corban M. T., Duarte-Garcia A, Mc Bane R. D, Matteson E. L, Lerman L. O., Lerman A. Antiphospholipid syndrome. Role of vascular endothelial cells and implications for risk stratification and targeted therapeutics. // J Am CollCardiol. - 2017. -69. - 2317-2330.
Costedoat-Chalumeau N., Guettrot-Imbert G., Leguern V. et al. Pregnancy and antiphospholipid syndrome // Rev. Med. Inter. - 2012. - V. 33. - P. 209-216.
D. Erkan Antiphospholipid Syndrome: Current Research Highlights and Clinical Insights // Springer-Verlag GmbH. — 2017. — 371 p. D. Erkan Force report on antiphospholipid syndrome treatment trends 14th International Congress on Antiphospholipid Antibodies: // Autoimmun. Rev. — 2014. —Vol. 13, № 6. — P. 685-696.
D. Sene, J. C. Piette, P. Cacoub Antiphospholipid antibodies, antiphospholipid syndrome and viral infections // Rev. Med. Intern. — 2009. — Vol. 30, № 2. — P. 135-141.
D’Ippolito S., Meroni P.L., Koike T. et al. Obstetric antiphospholipid syndrome: a recent classification for an old defined disorder. Autoimmun Rev. 2014; 13 (9): 901-8.
Danowski A., de Azevedo M., de Souza Papi J., Petri M. Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus // J. Rheumtol. - 2009. - V. 36. - P. 1195-1199
Danowski A., Kickler T., Petri M. Anti-p2-glycoprotein I: prevalence, clinical correlations, and importance of persistent positivity in patients with antiphospholipid syndrome and systemic lupus erythematosus // J. Rheumatol. - 2006. - V. 33. - P. 1775-1779.
de Groot P. G., Urbanus R. T. The significance of autoantibodies against 2-glycoprotein I // Blood. - 2012. - V. 120. - P. 266-274.
De Groot PG. Standardization of APA-tasting, a bridge too far? Proceedings of the 9th Meeting of the European Forum on Antiphospholipid Antibodies; 2013 May 16-18; Krakow, Poland. Krakow: Medycyna praktyczna; 2013.
de Laat B., Pengo V., Pabinger I. et al. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study // J. Thromb. Haemost. - 2009. - V. 7. - P. 1767-1773.
Di Simone N., Raschi E., Testoni C. et al. Pathogenic role of anti-^2- glycoprotein I antibodies in antiphospholipid associated fetal loss: characterisation of ^2-glycoprotein I binding to trophoblast cells and functional effects of anti-- glycoprotein I antibodies in vitro // Ann. Rheum. Dis. - 2005. - V. 64. - P. 462¬467.
Dunoyer-Geindre S., de Moerloose P., Galve-de Rochemonteix B. et al. NFKB is an essential intermediate in the activation of endothelial cells by anti- -glycoprotein 1 antibodies // Thromb. Haemost. - 2002. - V. - 88. - P. 851¬857.
E. Raschi, C. Testoni, D. Bosisio et al. Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies // Blood. - 2003. - V. 101. - P. 3495- 3500.
Erkan D., Pierangeli S.S., et al. Antiphospholipid Syndrome: Insights and Highlights from the 13th International Congress on Antiphospholipid Antibodies. New York: Springer. - 2012. - 312 p.
Evain-Brion D., Guibourdenche J., Tsatsaris V., Fournier T. Human trophoblast differentiation // Bull. Acad. Nat. Med. - 2009. - V. 193. - P. 1017¬1025.
Favaloro E. J., Mohammed S., Curnow J., Pasalic L. Laboratory testing for lupus anticoagulant (LA) in patients taking direct oral anticoagulants (DOACs): potential for false positives and false negatives. // Pathology. - 2019. - 51(3). - 292-300.
Favaloro EJ, Wong RCW. The antiphospholipid syndrome: diagnosis, pathogenesis, laboratory testing, and management. Seminars in Thrombosis and Hemostasis. Vol.38, N4/2012; 299-304.
Francis J., Rai R., Sebire N. J. et al. Impaired expression of endometrial differentiation markers and complement regulatory proteins in patients with recurrent pregnancy loss associated with antiphospholipid syndrome // Molec. Hum. Reprod. - 2006. - V. 12. - P. 435-442.
Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature // Blood. - 2003. - V. 101. - P. 1827-1832.
Galli M., Barbui T. Antiphospholipid syndrome: Clinical and diagnostic Utility of Laboratory Tests. // Semin in Thromb and Haem, 2005. 1. - p. 17-24.
Garcia, D. A. Khamashta M.A., Crowther M.A. How we diagnose and treat thrombotic manifestations of the antiphospholipid syndrome: a case-based review // Blood. - 2007. - Vol. 110. - P. 3122-3127.
Geis W., Branch D. W. Obstetric implications of antiphospholipid antibodies: pregancy loss and other complications // Clin. Obstet. Gynecol. - 2001. Vol. 44. - N 1. - P. 2-10.
Gerosa M., de Angelis V., Tresoidi L. et al. Complement involvement in antiphospholipid antibody-mediated placental damage: prospective study in APS pregnant women // Ann. Rheum. Dis. - 2009. - V. 68. - article 210.
Giannakopoulos B., Krilis S. A. The pathogenesis of antiphospholipid syndrome // N. E. J. Med. - 2013. - V. 368. - P. 1033-1044.
Girardi G., Berman J., Redecha P. et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome // J. Clin. Invest. - 2003. -V. 112. -P. 1644-1654.
Girardi G., Redecha P., Salmon J. E. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation // Nat. Med. - 2004.- V. 10. - P. 1222-1226.
Gomez-Puerta, J. A. Diagnosis and classification of the antiphospholipid syndrome / J. A. Gomez-Puerta, R. Cervera // J. Autoimmun. — 2014. — Vol. 48-49. — P. 20-25.
Greaves M. Antiphospholipid syndrome: state of the art with emphasis on laboratory evaluation // Haemostasis. - 2000. - Vol. 30 (Suppl. 2). - P. 16-25.
Gris J. C., Bouvier S., Molinari N. et al. Comparative incidence of a first thrombotic event in purely obstetric antiphospholipid syndrome with pregnancy loss: the NOH-APS observational Study // Blood. - 2012. - V. 119. - P. 2624-2632.
Gris J. C., Quere I., Sanmarco M. et al. Antiphospholipid and antiprotein Syndromes in non-trombotic, non autoimmune women with unexplained recurrent primary early foetal loss // Thromb. Haemost. - 2000. - Vol. - 84. -P. 228-236.
Harper B. E., Wills R., Pierangeli S. S. Pathophysiological mechanisms in antiphospholipid syndrome // Int. J. Clin. Rheumatol. - 2011. - V. 6. -P. 157-171.
Hell L., Ay C., Posch F., Gebhart J., Koder S., Mackman N., Pabinger I., Thaler J. Lowex tracellular vesicle associated tissue factoractivity inpatients with persistentlupusanti coagulantand a history of throm bosis. // Ann. Hematol. - 2019. - 98(2). - 313-319.
I. Rodriguez-Pinto, G. Espinosa, R. Cervera Rodriguez-Pinto, I., .Catastrophic antiphospholipid syndrome: The current managementapproach// Best Pract. Res. Clin. Rheumatol. — 2016. — Vol. 30, № 2. — P. 239-249.
Jovanovic M., Bozic M., Kovacevic T. et al. Effects of anti¬phospholipid antibodies on a human trophoblast cell line (HTR-8/SVneo) // Acta Histochem. - 2010. - V. 112. - P. 34-41.
Kawai T., Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity // Immunity. - 2011. - V. 34. - P. 637¬650.
Keeling D, Mackie I, Moore GW, et al.; British Committee for Standards in Haematology. Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol. 2012 Apr;157(1):47-58. DOI: 10.1111 / j.1365-2141.2012.09037.x. Epub 2012 Feb 8.
122. Keeling D. Guidelines on the investigation and management of antiphospholipid syndrome // British Journal of Haematology. - 2012. - Vol. 157. - P. 47-58.
L. Andreoli Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a criticalreview of the literature // Arthritis Care Res. (Hoboken). — 2013. —Vol. 65, № 11. — P. 1869-1873.
Lakos G, Favaloro E J, Harris E N, et al. International consensus guidelines on anticardiolipin and anti-beta2-glycoprotein i testing: a report from the APL Task Force at the 13th International Congress on Antiphospholipid Antibodies. Arthritis Rheum 2012; 64(1):1—10.
Lesley J. Tofacitinib: A Review of its Use in Adult Patients with Rheumatoid Arthritis. Drugs 2013; 73: 857-74. A
Levine J. S., Branch D. W., Rauch J. The antiphospholipid syndrome // N. Engl. J. Med. - 2002. - V. 346. - P.752-763.
Lin W. S., Chen P. C., Yang C. D. et al // Some antiphospholipid antibodies recognize conformational epitopes shared by p2-glycoprotein I and the homologous catalytic domains of several serine proteases // Arthritis. Rheum. - 2007. - V. 56. - P. 1638-1647.
Linnemann B. Antiphospholipid syndrom. // In: Dietel, Suttorp, Zeitz. Harrisons Innere Medizin. - ABWW issenschaftsverlag 19. Auflage 2016; Berlin, Deutschland.- 2623-2625.
Linnemann B. Antiphospholipid syndrome - anupdate. // Vasa.- 2018. - 47. - 451-464.
M. Biggioggero, P. L. Meroni The geoepidemiology of the antiphospholipid antibody syndrome // Autoimmun. Rev. — 2010. — Vol. 9, № 5. — P. 299-304.
131. M. Khamashta Antiphospholipid syndrome / [et al.] // Best Pract. Res. Clin. Rheumatol. — 2016. —Vol. 30, № 1. — P. 133-148.
Mahler M., Norman G. L., Meroni P. L., Khamashta M. Autoantibodies to domain 1 of beta 2 glycoprotein 1: a promising candidate biomarker for risk management in antiphospholipid syndrome // Autoimm. Rev. - 2012. - V. 12. - P. 313-317.
Marchetti T., Cohen M., de Moerloose P. Obstetrical antiphospholipid syndrome: from the pathogenesis to the clinical and therapeutic implications // Clin. Develop. Immun. Volume 2013, Article ID 159124, http://dx.doi.org/10.1155/2013/159124
Mayer M., Cerovec M., Rados M., Cikes N. Antiphospholipid syndrome and central nervous system // Clin. Neurol. Neurosurg. 2010. -Vol.112 (7).-P.602-608.
Mc Neil H., Simpson R., Chesterman C., Krilis S. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding . ... _ . . ■ T /' , T inhibitor of coagulation: p2-glycoprotem I (apolipoprotein H) // Proc. Natl. Acad. Sci. USA. - 1990. - V. 87. - P. 4120-4124.
Mehdi A, Uthman I, Khamashna M. Treatment of antiphospholipid syndrome. IntJClinRheumatol 2010; 5 (2): 241-54.
Mekinian A., Lachassine E., Nicaise-Roland P. et al. European registry of babies born to mothers with anti-phospholipid syndrome // Ann. Rheum. Dis. - 2013. - V. 72. - P. 217-222.
Merashli M., Alves J., Ames P. R. Clinicalrelevance of antiphospholipidanti bodiesin systemics clerosis: A systematic reviewand meta¬analysis. // Semin Arthritis Rheum. - 2017. - 46(5). - 615-624.
Meroni P. L., Borghi M. O., Raschi E., Tedesco F. Pathogenesis of antiphospholipid syndrome: understanding the antibodies // Nat. Rev. Rheum. - 2011. - V. 7. - P. 330-339.
Meroni P. L., Tedesco F., Locati M. et al. Anti-phospholipid antibody mediated fetal loss: Still an open question from a pathogenic point of view // Lupus. - 2010. - V. 19. - P. 453-456.
141. Meroni P.L., Gerosa M., Raschi E. et al. Updating on the pathogenic mechanisms 5 of the antiphospholipid antibodies-associated pregnancy loss // Clin. Rev. Allerg. Imm. - 2008. - V. 34. - P. 332-337.
Miyakis S. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) // Thromb. Haemost. - 2006. - Vol. 4. -P. 295-306.
Miyakis S., Lockshin M. D., Atsumi T. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) // J. Thromb. Haemost. - 2006. - V. 4. - P. 295-306.
Morales J. M., Serrano M., Martinez-Flores J. A., Perez D., Serrano A. Antiphospholipid Syndrome and Renal Allograft Thrombosis. // Transplantation. - 2019. - 103(3). - 481-486.
Mulla M. J., Brosens J. J., Chamley L. W. et al. Antiphospholipid antibodies induce a proinflammatory response in first trimester trophoblast via the TLR4/MyD88 pathway // Am. J. Reprod. Imm. - 2009. - V. 62. - P. 96-111.
Mulla M. J., Myrtolli K., Brosens J. J. et al. Antiphospholipid antibodies limit trophoblast migration by reducing IL-6 production and STAT3 activity // Am. J. Reprod. Immun. - 2010. - V. 63. - P. 339-348.
Nodler J., Moolamalla S. R., Ledger E. M. et al. Elevated antiphospholipid antibody titers and adverse pregnancy outcomes: analysis of a population-based hospital dataset // BMC Pregn. Child. - 2009. - V. 9. - article 11.
of action and treatment / A. Tripodi, P.G. de Groot, V. Pengo // Journal of Petri M. Epidemiology of the anti-phospholipid antibody syndrome // J. Autuimmun. 2000. - Vol.15. - P.145 -151.
Pontara E., Banzato A., Bison E., Cattini M. G., Baroni G. & Denas G. Thrombocytopenia in high-risk patients with antiphospholipid syndrome. // J Throm Haemost. - 2018. - 16. - 529-532.
Poulton K., Rahman A., Giles I. Examining how antiphospholipid antibodies activate intracellular signaling pathways: a systematic review // Sem. Arthritis Rheum. - 2012. - V. 41. - P. 720-736.
Prinz N., Clemens N., Strand D. et al. Antiphospholipid antibodies induce translocation of TLR7 and TLR8 to the endosome in human monocytes and plasmacytoid dendritic cells // Blood. - 2011. - V. 118. - P. 2322-2332.
R. Rai, T. Swetha Association of anti-phospholipid antibodies with connective tissue diseases // Indian Dermatol. Online J. — 2015. — Vol. 6, № 2. — P. 89-91.
Rai R. S., Regan L., Clifford K. et al. Antiphospholipid antibodies and ^2-glycoprotein-I in 500 women with recurrent miscarriage: results of a comprehensive screening approach // Hum. Reprod. - V. 10. - P.2005.
Rasool Z. S., Tiwari V. Biochemistry, Lupus Anticoagulant. // Stat Pearls [Internet]. - 2019. - Treasure Island (FL): Stat Pearls Publishing.
Richard, C.W. Clinical Features, Diagnosis, and Management of the Ruffatti A., Del Ross T., Ciprian M. et al. Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study // Ann. Rheum. Dis. - 2009. - V. 68. - P. 397-399.
Ruiz-Irastorza G., Crowther M., Branch W., Khamashta M. A. Antiphospholipid syndrome. Lancet. 2010; 376 (9751): 1498-509.
Salmon J. E., Girardi G., Holers V. M. Complement activation as a mediator of antiphospholipid antibody induced pregnancy loss and thrombosis // Ann. Rheum. Dis. - 2002. - V. 61. - P. ii46-50.
Sanna G., Bertolaccini M. L., Hughes G. R. V. Hughes Syndrome. The Antiphospholipid Syndrome: A New Chapter in Neurology // Ann. N.Y. Acad. Sci. 2005. - Vol.1051. - P. 465 - 486.
Satta N., Dunoyer-Geindre S., Reber G. et al. The role of TLR2 in the inflammatory activation of mouse fibroblasts by human antiphospholipid antibodies // Blood. - 2007. -V. 109. -P. 1507-1514.
Satta N., Kruithof E. K. O., Fickentscher C. et al. Toll-like receptor 2 mediates the activation of human monocytes and endothelial cells by antiphospholipid antibodies // Blood. - 2001. - V. 117. - P. 5523-5531.
Satta N., Kruithof E. K. O., Reber G., de Moerloose P. Induction of TLR2 expression by inflammatory stimuli is required for endothelial cell responses to lipopeptides // Molec. Immun. - 2008. - V. 46. - P. 145-157.
Savaj S, Vaziri N. An overview of recent advances in pathogenesis and diagnosis of preeclampsia //Iran J. Kidney Dis. 2012. -Vol. 6(5).-P.334-338.. Sciascia S., Sanna G., Khamashta M. A. et al. The estimated frequency of antiphospholipid antibodies in young adults with cerebrovascular events: a systematic review // Ann. Rheum. Dis. — 2014. — Vol. 18. — P. 205 663.
Shamonki J. M., Salmon J. E., Hyjek E., Baergen R. N. Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies // Am. J. Obst. Gyn. - 2007. - V. 196. - P. 167.e1- 167.e5.
Skrzypczak J., Jasinski P., Wirstlein P. et al. Histologic changes in placenta and chorion of women with antiphospholipid syndrome and inherited thrombophilia // Ginekol. Polska. - 2011. - V. 82. - P. 652-663.
Stojanovich L1, KonticM, Smiljanic D, Djokovic A, Stamenkovic B, Marisavljevic D. Association between nonthrombotic neurological and cardiac manifestations in patients with antiphospholipid syndrome. Clin Exp Rheumatol. 2013 Sep-Oct;31(5):756-60. Epub 2013 Jul 30.
Tripodi, A. Antiphospholipid syndrome: laboratory detection, mechanisms Urbanus RT. Lupus anticoagulant measurement: to mix or not to mix. Proceedings of the 9th Meeting of the European Forum on Antiphospholipid Antibodies; 2013 May 16-18; Krakow, Poland. Krakow: Medycyna praktyczna; 2013.
van Horn J.T., Craven C., Ward K. et al. Histologic features of placentas and abortion specimens from women with antiphospholipid and antiphospholipis-like syndromes // Placenta. - 2004. - V. 25. - P. 642-648.
Vega-Ostertag M., Casper K., Swerlick R. et al. Involvement of p38 MAPK in the upregulation of tissue factor on endothelial cells by antiphospholipid antibodies // Arthritis Rheum. - 2005. - V. 52. - P. 1545-1554.
Vianna J. L., Khamashta M. A., Ordi-Ros J. et al. Comparison of the primary and secondary antiphospholipid syndrome: a European Multicenter Study of 114 patients // Am. J. Med. - V. 96. - P. 3-9. Virella G. Medical Immunology. - 5 ed. - Marcel Dekker, Inc., 2001. - 667 p.
Von Landenberg P., von Landenberg C., Scholmerch J., Lackner K. J. Antiphospholipid syndrome. Pathogenesis, molecular basis and clinical aspects // Med. Clin. - 2001. - Vol. 96. - N 6. - P. 331-342.
Wilson W., Gharavi A., Koike T. et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome // Arthritis Rheumotol. - 1999. - V.42. - P. 1309-1311.
